Curriculum
Course Description:The liposomal “commercial” lipid pool has little variation, and “fancy” lipids (e.g., potentially useful for gene and DNA/RNA delivery, immunological targeting, fusogenic/cationic lipids) are mostly avoided. Shaping lipids into liposomes is becoming more of an engineering act than an art form. The first bioequivalent doxorubicin liposome has been approved.
Featuring Alex Nivorozhkin, Ph.D., Neo-Advent Technologies LLC
Access Duration:Access to this course expires 60 days from the date of registration or until you mark the course ‘Complete’ – whichever occurs first.